Every material Form 8-K Revvity has filed with the SEC since February 01, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Revvity, Inc. reported third quarter 2026 revenue of $729 million and GAAP EPS from continuing operations of $0.56, compared to $699 million and $0.41 a year ago. The company raised its full year 2026 pro forma guidance, forecasting total revenue of approximately $2.86 billion and pro forma adjusted EPS of $5.40-$5.45. Additionally, the company is holding its Investor Day on November 13, 2026.
Revenue for the third quarter ended October 4, 2026 was $729 million, with pro forma revenue of $710 million representing 7% pro forma organic growth.
GAAP EPS from continuing operations was $0.56, while adjusted EPS from continuing operations reached $1.38.
Full year 2026 pro forma guidance forecasts total revenue of approximately $2.86 billion and pro forma adjusted EPS of $5.40-$5.45.
Revvity reported second-quarter 2026 revenue of $730 million, up from $720 million a year earlier, and GAAP EPS from continuing operations of $0.48 versus $0.47. The company raised its full-year 2026 guidance and agreed to sell its China Immunodiagnostics business for up to $200 million, a deal it expects to close by the end of 2027.
Q2 2026 revenue was $730 million, versus $720 million in Q2 2025; adjusted EPS from continuing operations was $1.41, versus $1.18
Adjusted EPS includes approximately $0.11 from tariff-related refunds, according to the filing
Full-year 2026 pro forma adjusted EPS guidance is $5.30-$5.40, and pro forma revenue guidance is $2.83-$2.86 billion, excluding China IDX
China IDX sale for up to $200 million, signed July 31, 2026; expected to close by the end of 2027, subject to conditions and regulatory approvals
Revvity reported first-quarter 2026 revenue of $711 million, up from $665 million a year earlier, and adjusted EPS of $1.06, up from $1.01. The company also said it intends to divest its China Immunodiagnostics business, under a letter of intent for up to $200 million, and updated its full-year 2026 guidance on a pro forma basis.
Q1 2026 revenue was $711 million vs $665 million a year earlier; GAAP EPS from continuing operations was $0.37 vs $0.35.
Adjusted operating income was $168 million vs $170 million, and adjusted operating margin was 23.6% vs 25.6%.
Full-year 2026 pro forma guidance: total revenue of $2.81-$2.84 billion and pro forma adjusted EPS of $5.20-$5.30.
China Immunodiagnostics was about 6% of 2025 revenue; a letter of intent was signed April 16, 2026, with a definitive agreement expected in Q2 2026 and completion expected in 2027.
Revvity reported fourth-quarter 2025 revenue of $772 million, up 6% from a year earlier, and adjusted EPS from continuing operations of $1.70, up from $1.42. For full-year 2025, revenue rose to $2.86 billion and adjusted EPS reached $5.06, though GAAP EPS fell to $2.07 from $2.20. The company also initiated 2026 guidance, which calls for revenue of $2.96 billion to $2.99 billion and adjusted EPS of $5.35 to $5.45.
Q4 2025 GAAP EPS was $0.87 vs. $0.78 a year earlier; GAAP operating income fell to $112 million from $119 million.
Diagnostics Q4 revenue rose 10% to $390 million; Life Sciences Q4 revenue rose 2% to $382 million.
Full-year 2025 revenue was $2,856 million vs. $2,755 million in 2024; GAAP EPS was $2.07 vs. $2.20.
2026 guidance: revenue of $2.96 billion to $2.99 billion, organic revenue growth of 2% to 3%, and adjusted EPS of $5.35 to $5.45.
Revvity said it expects full-year 2025 adjusted earnings per share to exceed the upper end of its $4.90-$5.00 guidance from October 27, 2025. It also preliminarily estimated fourth-quarter revenue of approximately $772 million and full-year 2025 revenue of approximately $2,855 million, with final results due February 2, 2026. For shareholders, this is an early signal that profit and revenue are running ahead of the prior outlook, though the figures remain preliminary until the full release.
Full-year 2025 adjusted EPS now expected to exceed the upper end of the $4.90-$5.00 guidance
Fourth-quarter 2025 revenue expected at approximately $772 million, up approximately 6% reported and 4% organic
Full-year 2025 revenue expected at approximately $2,855 million, up approximately 4% reported and 3% organic
Full fourth-quarter and full-year 2025 results and earnings call scheduled for February 2, 2026
Revvity reported third-quarter 2025 results on October 27, 2025. Revenue rose to $699 million from $684 million, but GAAP EPS fell to $0.40 from $0.77 and adjusted EPS fell to $1.18 from $1.28. The company raised its full-year 2025 adjusted EPS guidance to $4.90 to $5.00 and authorized a new two-year $1 billion share repurchase program.
Q3 revenue was $699 million vs. $684 million a year earlier, up 2% reported and 1% organic.
Q3 adjusted EPS was $1.18 vs. $1.28; GAAP EPS was $0.40 vs. $0.77.
Full-year 2025 adjusted EPS guidance raised to $4.90 to $5.00; revenue guidance updated to $2.83 to $2.88 billion; organic growth guidance of 2% to 4% reaffirmed.
New two-year $1 billion share repurchase program replaces the remainder of the program announced in October 2024.
Revvity's Board appointed Vice President and Controller Anita Gonzales as Vice President and Chief Accounting Officer, effective immediately, on October 23, 2025. She has been the company's controller since May 2023 and joined in March 2021. The filing does not describe any change to her compensation.
Anita Gonzales, 49, appointed Vice President and Chief Accounting Officer on October 23, 2025, effective immediately
She previously served as Vice President and Controller since May 2023 and joined Revvity in March 2021 as Senior Director of Integration and Controllership Initiatives
Prior to Revvity, she spent ten years at General Electric Company, and earlier worked at PricewaterhouseCoopers
She is a Certified Public Accountant with degrees from the University of Texas at Austin
Revvity reported second-quarter 2025 revenue of $720 million, up from $692 million a year earlier, and GAAP EPS of $0.46 versus $0.45. Adjusted EPS from continuing operations fell to $1.18 from $1.22, and the company raised its full-year 2025 revenue guidance to $2.84-$2.88 billion while setting adjusted EPS guidance at $4.85 to $4.95.
Q2 2025 revenue was $720 million, up 4% reported and 3% organic, from $692 million a year earlier.
GAAP EPS was $0.46 versus $0.45; adjusted EPS from continuing operations was $1.18 versus $1.22.
Adjusted operating profit margin was 26.6%, down from 28.8% a year earlier.
Full-year 2025 revenue guidance was raised to $2.84-$2.88 billion, reflecting foreign currency changes; adjusted EPS guidance is $4.85 to $4.95.
Revvity reported first-quarter 2025 revenue of $665 million, up from $650 million a year earlier, and GAAP EPS of $0.35 versus $0.21. Adjusted EPS from continuing operations was $1.01 versus $0.98. The company raised its full-year 2025 revenue guidance to $2.83-$2.87 billion, citing currency changes, and reaffirmed its organic growth and adjusted EPS guidance.
Q1 2025 revenue of $665 million, up 2% reported and 4% organic, versus $650 million a year earlier.
GAAP EPS of $0.35 versus $0.21; adjusted EPS from continuing operations of $1.01 versus $0.98.
Full-year 2025 revenue guidance raised to $2.83-$2.87 billion; organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00 reaffirmed.
Diagnostics adjusted operating margin fell to 22.8% from 24.3%, while Life Sciences margin rose to 31.1% from 30.0%.
Revvity reported fourth-quarter 2024 revenue of $729 million, up from $696 million a year earlier, and GAAP EPS of $0.78 versus $0.64. For full-year 2024, adjusted EPS from continuing operations rose to $4.90 from $4.65 on revenue that was essentially flat at $2,755 million. The company also initiated 2025 guidance of $2.80-$2.85 billion in revenue and $4.90-$5.00 in adjusted EPS, which gives shareholders its outlook for the year.
Q4 2024 GAAP EPS $0.78 vs $0.64; adjusted EPS from continuing operations $1.42 vs $1.25
Q4 2024 GAAP operating income $119 million vs $77 million; GAAP operating margin 16.3% vs 11.1%
Full-year 2024 GAAP EPS $2.20 vs $5.55 in 2023; the 2023 figure included $4.11 per share from discontinued operations
2025 guidance: total revenue $2.80-$2.85 billion and adjusted EPS $4.90-$5.00
Revvity said preliminary fourth-quarter 2024 revenue growth of about 5% reported and 6% organic, which it expects to produce revenue of about $730 million. It also now expects full-year 2024 adjusted earnings per share to meet or exceed guidance given on November 4, 2024. Full results are due before market open on January 31, 2025.
Q4 2024 reported revenue growth expected at about 5%, organic growth about 6%
Q4 2024 revenue expected at approximately $730 million
Full-year 2024 adjusted EPS expected to meet or exceed the November 4, 2024 guidance
Full Q4 and full-year 2024 results and earnings call on January 31, 2025; CEO Prahlad Singh presents at J.P. Morgan Healthcare Conference on January 13, 2025
Revvity and its subsidiary Revvity Health Sciences entered a new $1.5 billion unsecured revolving credit facility dated January 7, 2025, with Bank of America as administrative agent. The new facility replaces the prior $1.5 billion facility, which was terminated the same day and had been set to run through August 24, 2026; the new one is available through January 7, 2030. As of January 7, 2025, the borrowers had no borrowings and $4.2 million of letters of credit outstanding.
Facility size of $1.5 billion, available through January 7, 2030
Replaces prior $1.5 billion credit agreement dated August 24, 2021, which was terminated January 7, 2025
No borrowings and $4.2 million of letters of credit outstanding as of January 7, 2025
Interest priced at base rate or term SOFR plus a spread tied to Revvity's credit rating
Revvity reported third-quarter 2024 revenue of $684 million, up 2% from $671 million a year earlier, and adjusted EPS from continuing operations of $1.28, up from $1.18. The company raised its full-year 2024 adjusted EPS guidance to $4.83 to $4.87 and authorized a new two-year $1 billion share repurchase program.
Q3 2024 revenue of $684 million vs. $671 million a year earlier; GAAP EPS of $0.77 vs. $0.08
Q3 adjusted EPS from continuing operations of $1.28 vs. $1.18; adjusted operating profit margin of 28.3% vs. 27.5%
Full-year 2024 adjusted EPS guidance raised to $4.83 to $4.87; revenue guidance set at $2.75 to $2.77 billion, reflecting currency changes
New two-year $1 billion share repurchase program replaces the remainder of the program announced in May 2023; Investor Day on November 21, 2024
Revvity reported second-quarter 2024 revenue of $692 million, down from $709 million a year earlier, while GAAP EPS rose to $0.45 from $0.28 and adjusted EPS from continuing operations was $1.22 versus $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80 and set revenue guidance at $2.77-$2.79 billion, citing currency changes and assumed 2% organic revenue growth. Shareholders see higher profit measures alongside a lower top line, with Life Sciences revenue down 7%.
Q2 2024 revenue was $692 million versus $709 million a year earlier; reported revenue fell 2% and organic revenue fell 1%.
GAAP EPS was $0.45 versus $0.28; adjusted EPS from continuing operations was $1.22 versus $1.21.
Full-year 2024 adjusted EPS guidance raised to $4.70-$4.80; revenue guidance updated to $2.77-$2.79 billion.
Life Sciences revenue fell 7% to $314 million; Diagnostics revenue rose 1% to $378 million.
Revvity reported first-quarter 2024 revenue of $650 million, down from $675 million a year earlier, and adjusted EPS from continuing operations of $0.98, down from $1.01. The company reaffirmed its full-year adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%, while updating its full-year revenue guidance to $2.76-$2.82 billion to reflect foreign currency changes.
Q1 2024 revenue $650 million vs $675 million a year earlier; organic growth (3)%
Life Sciences revenue fell 8% to $303 million; Diagnostics was flat at $347 million
GAAP EPS $0.21 vs $4.50 a year earlier; the prior-year figure included discontinued operations income
Full-year 2024 adjusted EPS guidance of $4.55-$4.75 reaffirmed; revenue guidance updated to $2.76-$2.82 billion
Revvity reported fourth-quarter 2023 revenue of $696 million, down from $741 million a year earlier, and adjusted EPS from continuing operations of $1.25, down from $1.41. For full year 2023, adjusted EPS fell to $4.65 from $6.92 and revenue fell to $2,751 million from $3,313 million, and the company initiated 2024 guidance of $2.79-$2.85 billion in revenue and $4.55-$4.75 in adjusted EPS.
Q4 2023 revenue was $696 million, down 6% on a reported basis from $741 million; GAAP EPS was $0.64 versus $1.01.
Full year 2023 adjusted EPS from continuing operations was $4.65, versus $6.92 in 2022; Diagnostics full-year revenue fell 28% to $1,459 million.
2024 guidance: total revenue of $2.79-$2.85 billion and adjusted EPS of $4.55-$4.75.
Full year 2023 GAAP EPS of $5.55 was boosted by income from discontinued operations of $4.11 per share.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Revvity filing is on SEC EDGAR ↗. 8-K briefs of other companies →